4.7 Article

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

期刊

出版社

MDPI
DOI: 10.3390/ijms22158277

关键词

novel psychoactive substance; pyrovalerone; cathinone; monoamine; transporter; receptor; inhibition

资金

  1. Federal Office of Public Health [16.921318]

向作者/读者索取更多资源

Pyrovalerone cathinones are potent DAT and NET inhibitors with high selectivity, potentially leading to strong psychostimulant effects and high abuse liability.
Pyrovalerone cathinones are potent psychoactive substances that possess a pyrrolidine moiety. Pyrovalerone-type novel psychoactive substances (NPS) are continuously detected but their pharmacology and toxicology are largely unknown. We assessed several pyrovalerone and related cathinone derivatives at the human norepinephrine (NET), dopamine (DAT), and serotonin (SERT) uptake transporters using HEK293 cells overexpressing each respective transporter. We examined the transporter-mediated monoamine efflux in preloaded cells. The receptor binding and activation potency was also assessed at the 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors. All pyrovalerone cathinones were potent DAT (IC50 = 0.02-8.7 mu M) and NET inhibitors (IC50 = 0.03-4.6 mu M), and exhibited no SERT activity at concentrations < 10 mu M. None of the compounds induced monoamine efflux. NEH was a potent DAT/NET inhibitor (IC50 = 0.17-0.18 mu M). 4F-PBP and NEH exhibited a high selectivity for the DAT (DAT/SERT ratio = 264-356). Extension of the alkyl chain enhanced NET and DAT inhibition potency, while presence of a 3,4-methylenedioxy moiety increased SERT inhibition potency. Most compounds did not exhibit any relevant activity at other monoamine receptors. In conclusion, 4F-PBP and NEH were selective DAT/NET inhibitors indicating that these substances likely produce strong psychostimulant effects and have a high abuse liability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

Anna M. Becker, Friederike Holze, Tanja Grandinetti, Aaron Klaiber, Vanja E. Toedtli, Karolina E. Kolaczynska, Urs Duthaler, Nimmy Varghese, Anne Eckert, Edna Grunblatt, Matthias E. Liechti

Summary: The study examined the interaction between escitalopram and psilocybin in the treatment of depression and anxiety. Escitalopram pretreatment was found to reduce certain negative effects of psilocybin, but further research is needed to fully understand the interactions between antidepressants and psilocybin in patients with psychiatric disorders.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Pharmacology & Pharmacy

Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines

Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti

Summary: The psychedelic alkaloids, scalines and 3C-scalines, were found to have similar effects to mescaline and could potentially be used as novel therapeutics for psychedelic-assisted therapy. These compounds interacted with various monoamine receptors, with higher affinity observed at 5-HT2A and 5-HT2C receptors.

FRONTIERS IN PHARMACOLOGY (2022)

Article Clinical Neurology

Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA

Karolina E. Kolaczynska, Paula Ducret, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti, Dino Luethi

Summary: This article examines the pharmacological properties of MDA analogs and related amphetamine-based compounds, including monoamine uptake inhibition and release, as well as transporter and receptor binding and activation properties. The study finds that some MDA analogs have similar pharmacological profiles to MDMA, while others have more pronounced dopaminergic activity. Further research on the pharmacokinetics and pharmacodynamics of these drugs is needed to better evaluate their risks and therapeutic potential.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Meeting Abstract Biochemistry & Molecular Biology

Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted 2,5-Dimethoxyamphetamines

Dino Luethi, Deborah Rudin, Marius C. Hoener, Mattias E. Liechti

FASEB JOURNAL (2022)

Meeting Abstract Biochemistry & Molecular Biology

Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α-Desmethyl (2C) Analogues

Deborah Rudin, Dino Luethi, Marius C. Hoener, Matthias E. Liechti

FASEB JOURNAL (2022)

Article Neurosciences

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Friederike Holze, Laura Ley, Felix Muller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sebastian Silva Kuehne, Marc A. Roder, Urs Duthaler, Karolina E. Kolaczynska, Nimmy Varghese, Anne Eckert, Matthias E. Liechti

Summary: This study compared the subjective and autonomic effects of LSD and psilocybin, finding that the higher doses of both substances produced similar subjective effects, but psilocybin had weaker effects at a lower dose. Additionally, LSD and psilocybin showed differences in their effects on heart rate and blood pressure.

NEUROPSYCHOPHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

Effects of acute and chronic administration of trace amine-associated receptor 1 (TAAR1) ligands on in vivo excitability of central monoamine-secreting neurons in rats

Daniil Grinchii, Marius C. Hoener, Talah Khoury, Roman Dekhtiarenko, Reyhaneh Nejati Bervanlou, Daniela Jezova, Eliyahu Dremencov

Summary: Trace amine-associated receptor 1 (TAAR1) has been identified as a potential target for future antidepressant, antipsychotic, and anti-addiction drugs. Studies have shown that TAAR1 agonists can produce antidepressant, antipsychotic, and anti-addiction behavioral effects in rodents and primates, and these effects are associated with the modulation of serotonin (5-HT) and dopamine.

MOLECULAR PSYCHIATRY (2022)

Article Neurosciences

TAAR1 Regulates Purinergic-induced TNF Secretion from Peripheral, But Not CNS-resident, Macrophages

David A. Barnes, Marius C. Hoener, Craig S. Moore, Mark D. Berry

Summary: This study reveals the role of Trace amine-associated receptor 1 (TAAR1) in modulating cytokine secretion and metabolic profiles in peripherally-derived macrophages. It also suggests a potential therapeutic target for inflammatory disorders. However, TAAR1 does not have the same effect in CNS-resident macrophages.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2023)

Article Neurosciences

Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines

Adam L. Halberstadt, Dino Luethi, Marius C. Hoener, Daniel Trachsel, Simon D. Brandt, Matthias E. Liechti

Summary: This study investigated the structure-activity relationships of 4-thio-substituted phenylalkylamines and found that these compounds have psychedelic effects, supporting their classification as psychedelics.

PSYCHOPHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Activation of trace amine-associated receptor 1 (TAAR1) transiently reduces alcohol drinking in socially housed mice

Bartosz Adam Frycz, Klaudia Nowicka, Anna Konopka, Marius Christian Hoener, Ewa Bulska, Leszek Kaczmarek, Marzena Stefaniuk

Summary: Alcohol dependence is characterized by abnormal dopamine release in the brain. TAAR1, a receptor that regulates dopamine neurotransmission, may be a target for treating addiction. This study examined the effects of TAAR1 activation on alcohol consumption in mice and found that activation of TAAR1 reduces alcohol drinking and preference. The findings suggest that TAAR1 is a promising target for treating alcohol abuse and relapse.

ADDICTION BIOLOGY (2023)

Review Neurosciences

Translational molecular imaging and drug development in Parkinson's disease

Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawood, Catherine Gebhard, Thomas Wichmann, Wolfgang Sippl, Marius Hoener, Ernest Arenas, Steven H. Liang

Summary: Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily affecting the elderly. PD is characterized by nigrostriatal loss and the formation of misfolded alpha-synuclein protein aggregates. Motor symptoms can be managed with dopaminergic therapy initially, but ultimately become unresponsive. Molecular imaging techniques such as PET and SPECT can be used to study PD.

MOLECULAR NEURODEGENERATION (2023)

Correction Neurosciences

Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques (vol 44, pg 1485, 2019)

Anushka V. Goonawardena, Stephen R. Morairty, Ryan Dell, Gabriel A. Orellana, Marius C. Hoener, Tanya L. Wallace, Thomas S. Kilduff

NEUROPSYCHOPHARMACOLOGY (2023)

Article Medicine, General & Internal

Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study

Roberta Noseda, Matteo Franchi, Alberto Pagnamenta, Laura Muller, Alison M. Dines, Isabelle Giraudon, Fridtjof Heyerdahl, Florian Eyer, Knut Erik Hovda, Matthias E. Liechti, Oscar Miro, Odd Martin Vallersnes, Christopher Yates, Paul I. Dargan, David M. Wood, Alessandro Ceschi, Euro DEN Plus Res Grp

Summary: This study examined the characteristics and determinants of admission to critical care for patients presenting to the Emergency Department with acute recreational drug toxicity. The findings suggest that age, polydrug use, ethanol co-ingestion, and the use of specific drugs are factors associated with admission to critical care, while the use of cocaine, cannabis, heroin, and amphetamine, as well as ED arrival during the night, were associated with lower odds of admission to critical care.

JOURNAL OF CLINICAL MEDICINE (2023)

暂无数据